The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Self-citationPapahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., & Redemann, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11460 · Cited by 1,620
Self-citationGabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Self-citationReduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647
Self-citationGianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., & Martini, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2688 · Cited by 553
Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477
Self-citationMayer, L. D., Tai, L. C. L., Ko, D. S. C., Masin, D., Ginsberg, R. S., Cullis, P. R., & Bally, M. B. (1989) · PubMed · Cited by 353
Gabizón, A., Dagan, A., Goren, D., Barenholz, Y., & FUKS, Z. Y. (1982) · PubMed · Cited by 263
Berry, G., Billingham, M., Alderman, E., Richardson, P., Torti, F., Lum, B., Patek, A., & Martin, F. J. (1998) · Annals of Oncology · doi:10.1023/a:1008216430806 · Cited by 241
Self-citation
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Biodegradable polymeric nanoparticles based drug delivery systems
Kumari, A., Yadav, S. K., & Yadav, S. C. (2010) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2009.09.001 · Cited by 3,724
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Self-citationNanomedicine—Challenge and Perspectives
Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., & Fuchs, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802585 · Cited by 1,305
The role of lipid components in lipid nanoparticles for vaccines and gene therapy
Hald Albertsen, C., Kulkarni, J. A., Witzigmann, D., Lind, M., Petersson, K., & Simonsen, J. B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114416 · Cited by 1,185
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volkova, M., & Russell, R. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960645 · Cited by 872
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Form Follows Function: Nanoparticle Shape and Its Implications for Nanomedicine
Kinnear, C., Moore, T. L., Rodriguez-Lorenzo, L., Rothen-Rutishauser, B., & Petri-Fink, A. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00194 · Cited by 672
Kraft, J. C., Freeling, J. P., Wang, Z., & Ho, R. J. Y. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23773 · Cited by 606
Nanotechnology in Therapeutics: A Focus on Nanoparticles as A Drug Delivery System
Bamrungsap, S., Zhao, Z., Chen, T., Wang, L., Li, C., Fu, T., & Tan, W. (2012) · Nanomedicine · doi:10.2217/nnm.12.87 · Cited by 606
Carbon nanotubes for delivery of small molecule drugs
Wong, B. S., Yoong, S. L., Jagusiak, A., Panczyk, T., Ho, H. K., Ang, W. H., & Pastorin, G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.005 · Cited by 585
Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.005 · Cited by 557
Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., & Searson, P. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.036 · Cited by 527
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Ibrahim, M., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., Elgarhy, O. H., Sarhan, H. A., Hussein, A. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.031 · Cited by 465
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
Dinarvand, R., Sepehri, N., Manouchehri, Rouhani, & Atyabi, F. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s18905 · Cited by 453
Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers
Zhao, Z., Ukidve, A., Krishnan, V., & Mitragotri, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.002 · Cited by 444
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
Laginha, K. M., Verwoert, S., Charrois, G. J. R., & Allen, T. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0343 · Cited by 441
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438
Sequentially Responsive Shell‐Stacked Nanoparticles for Deep Penetration into Solid Tumors
Chen, J., Ding, J., Wang, Y., Cheng, J., Ji, S., Zhuang, X., & Chen, X. (2017) · Advanced Materials · doi:10.1002/adma.201701170 · Cited by 420
Cardiotoxicity of cytotoxic drugs
Schimmel, K. J. M., Richel, D. J., van den Brink, R. B. A., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.003 · Cited by 391
Siegel, R. W., Hu, E., Cox, D. M., Goronkin, H., Jelinski, L., Koch, C. C., Mendel, J., Roco, M. C., & Shaw, D. T. (1999) · Springer eBooks · doi:10.1007/978-94-015-9185-0 · Cited by 380
Anthracycline associated cardiotoxicity in survivors of childhood cancer
Lipshultz, S. E., Alvarez, J. A., & Scully, R. E. (2008) · Heart · doi:10.1136/hrt.2007.136093 · Cited by 379
Ishida, T., Harada, M., Wang, X. Y., Ichihara, M., Irimura, K., & Kiwada, H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.04.003 · Cited by 365
Liposomal encapsulated anti-cancer drugs
Hofheinz, R.-D., Gnad-Vogt, S. U., Beyer, U., & Hochhaus, A. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000167902.53039.5a · Cited by 355
Polymer–drug conjugates: Origins, progress to date and future directions
Kopeček, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.014 · Cited by 347
Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115725 · Cited by 334
Orlowski, R. Z., Voorhees, P. M., Garcia, R. A., Hall, M. D., Kudrik, F. J., Allred, T., Johri, A. R., Jones, P. E., Ivanova, A., Van Deventer, H. W., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2911 · Cited by 319
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
Lukyanov, A. N., Elbayoumi, T. A., Chakilam, A. R., & Torchilin, V. P. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.007 · Cited by 294
Crist, R. M., Grossman, J. H., Patri, A. K., Stern, S. T., Dobrovolskaia, M. A., Adiseshaiah, P. P., Clogston, J. D., & McNeil, S. E. (2013) · Integrative Biology · doi:10.1039/c2ib20117h · Cited by 265
Third consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp261 · Cited by 263
Liposomes in Cancer Therapy: How Did We Start and Where Are We Now
Fulton, M. D., & Najahi-Missaoui, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076615 · Cited by 258
Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin
Kim, J. O., Kabanov, A. V., & Bronich, T. K. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.019 · Cited by 255
Pharmaceutical nanotechnology: from the bench to the market
Mazayen, Z. M., Ghoneim, A. M., Elbatanony, R. S., Basalious, E. B., & Bendas, E. R. (2022) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-022-00400-0 · Cited by 208
“This new liposomal formulation lowered doxorubicin transport to the heart and kidney while increasing doxorubicin accumulation [108].”
BackgroundEvaluation of nanomedicines: stick to the basics
McNeil, S. E. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.73 · Cited by 126
Doxorubicin‐Induced Cardiomyopathy in Children
Mancilla, T. R., Iskra, B., & Aune, G. J. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180017 · Cited by 108
Metadata
- Authors
- Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., Henderson, R., Berry, G., & Gabizon, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2000-08
- Volume
- 11
- Issue
- 8
- Pages
- 1029-1034
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2148845753
- Cited by
- 618
- References
- 18
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.